Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06856655 · ClinicalTrials.gov registry record
Achieving Portal Access With Scorpion Post-Approval Study 2
A clinical trial, sponsored by Argon Medical Devices.
- Completed
- Registry status
- 82
- Enrollment target
NCT06856655: Completed study, sponsored by Argon Medical Devices.
NCT06856655 is a clinical trial that has completed, run by Argon Medical Devices. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06856655 has completed, sponsored by Argon Medical Devices.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
Primary Outcome
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein and confirmed by portogram
Interventions
- DEVICE Scorpion Portal Vein Access Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2024-03-28 |
What the finished NCT06856655 record still lists
NCT06856655 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Scorpion Portal Vein Access Kit is the first listed.
NCT06856655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06856655 about?
NCT06856655 is a clinical study titled "Achieving Portal Access With Scorpion Post-Approval Study 2". Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
What is the current status of trial NCT06856655?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2022-02-01. Estimated completion is 2024-03-28.
What interventions are being tested in trial NCT06856655?
The interventions under investigation include: Scorpion Portal Vein Access Kit (DEVICE).
Who is sponsoring clinical trial NCT06856655?
This trial is sponsored by Argon Medical Devices, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI